Summary:
Neuro-cognitive and degenerative (CNS) diseases, with Alzheimer’s leading, are among the most intractable and costly and distressing diseases. Without effective therapies with minimal side effects, these diseases will break the healthcare systems, patients and caregivers.
Current therapies are inadequate and so many standard pharmaceutical responses have failed in late stage trials.
Only the most innovative solutions will yield effective therapies.
Israel, with its history & culture of scientific innovative innovation, government support & early recognition of the challenges of CNS, is poised to be a leader in effective CNS therapies.
How can we make Israel’s leadership known to the world?
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
Ilsi conference biomed presentation brain game change israel leadership in cns hds 6 10-13
1. “Deeper understanding of how the brain operates
will enable us to better understand ourselves.”
His Excellency Shimon Peres, President of the
State of Israel
06/07/13
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 1
2. Israel Brain Technologies and the $1M
B.R.A.I.N. Prize
September 12, 2012:$1 Million Global B.R.A.I.N. Prize
Announced by Israel Brain Technologies. $1M Prize
for Breakthroughs in Neurotechnology
Inspired by Israeli President Shimon Peres, Prize Will
Recognize a Breakthrough Achievement in Brain
Technology That Will Change Lives.
Winner to be announced at BrainTech Israel 2013
Conference 14-15 October.
http://www.youtube.com/watch?v=QZ0rTxWTvIA&featur
06/07/13 10:12
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 2
3. Obama Brain Mapping Initiative
April 2, 2013. President Obama on Tuesday
announced a broad new research initiative, starting
with $100 million in 2014, to invent and refine new
technologies to understand the human brain
06/07/13 10:12
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 3
4. What are neurological conditions?
Neurological diseases and disorders are those which
affect the brain, spinal cord and nerves throughout
the body. They refer to a malfunction in a portion or
several areas of the nervous system, which cause a
number of difficulties to occur immediately or
progressively over time. Some of these challenges
include problems with mobility, mental tasks (such as
learning and memory), basic functions (such as
swallowing and breathing), or emotional changes in
mood. In the worst cases, a neurological deficit can
lead to a shortened life expectancy.
06/07/13 10:12
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 4
5. The USA Business Conference Board
give us a human reason for interest
Cognitive neuroscience, by showing us how we look
at the world, can teach us new ways to improve
performance.
Knowing how the brain works — how people think
and why they act and react as they do — can be an
advantage in the workplace, where leading change
and convincing people to follow are cornerstones of
effective leadership.
Decision making, it turns out, is not all logical; it is
emotional, too.
06/07/13 10:12
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 5
6. Huge and unsustainable costs as a
reason for concern, research & action.
The cost of caring for Americans with
Alzheimer's and other forms of dementia may now be
as high as $215 billion a year -- more than the cost of
caring for heart disease or cancer, a new study finds.
And that number is expected to escalate as the elderly
population grows.
06/07/13 10:12
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 6
7. There are, correct, emotional, human
reasons for brain disease focus
Americans fear developing Alzheimer’s disease more
than cancer, stroke, heart disease and any other life-
threatening illness, according to a Marist Institute
poll released this week on behalf of Home-Instead
Senior Care.
06/07/13 10:12
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 7
8. There is a visual ecomap of the large
extent of Israeli brain research
http://www.israelbrain.org/wp-content/uploads/2012/08/D
06/07/13 10:12
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 8
9. BioNess
BioNess is the world leader developing and marketing
Neuro-Stimulation devices for the leg and arm to give
victims of stroke and other neuro-conditions, such as
MS and CP, effective motion. The devices know the
relevant nerves and how to stimulate them to enable
patients to walk and grasp, for example.
06/07/13 10:12
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 9
10. BioNess enables young woman with MS
to resume full life
http://www.bioness.com/L300_for_Foot_Drop/In_the
06/07/13 10:12
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 10
11. Alpha Omega Engineering
Alpha Omega is a leader in developing and
marketing sophisticated and pioneering systems and
micro-electrodes that enable online neural
stimulation and recording for Neurosurgery &
Neuroscience
Customer base: About 500 hospitals and research labs
throughout the world
06/07/13 10:12
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 11
12. Alpha Omega systems for neuro-
surgery
The MicroGuide Pro™ by Alpha Omega is the world’s most advanced
intra-operative MER (Micro Electrode Recording) system for
functional neurosurgery - a comprehensive guidance unit available for
target localization in the surgical treatment of movement disorders.
NeuroNav Si™ is a state-of-the-art MER system used clinically in the
localization of surgical targets for the implantation of Deep Brain
Stimulators (DBS) or ablation of target structures, in the treatment of
neurological and psychiatric diseases. The NeuroNav Si ™ allows for
the safe an accurate introduction of electrodes into the brain, while
recording neural activity, stimulating neural tissue, and guiding the
user to the optimal target.
06/07/13 10:12
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 12
13. Insightec
InSightec® is the pioneer and global leader in MRI guided focused
ultrasound technology for image guided acoustic surgery.
InSightec’s ExAblate® Neuro integrates high intensity Focused
Ultrasound Surgery with continuous Magnetic Resonance imaging
(MRI) to provide a non invasive, acoustic surgery platform for treating
neurological disorders without ionizing radiation through an intact
skull.
ExAblate® is the first system to use the MRI guided focused
ultrasound technology. In November 2012, ExAblate received the CE
Mark for the treatment of three neurological disorders, Essential
Tremors, Parkinson's and Neuropathic Pain.
06/07/13 10:12
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 13
14. TMS—TransCranial Magnetic Stimulation
The next two companies use TMS technology
Transcranial magnetic stimulation (TMS) is a noninvasive
technique used to apply brief magnetic pulses to the brain.
The pulses are administered by passing high currents
through an electromagnetic coil placed adjacent to a
patient's scalp. The pulses induce an electric field in the
underlying brain tissue. When the induced field is above a
certain threshold, and is directed in an appropriate
orientation relative the brain's neuronal pathways,
localized axonal depolarizations are produced, thus
activating the neurons in the relevant brain structure.
06/07/13 10:12
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 14
15. Neuronix
Neuronix is the only company in the world that has developed a system
that is clinically proven to increase cognitive levels in early and mid-stage
Alzheimer’s patients every day, and, based on the CE mark, is selling
systems and treating patients every day.
Neuronix systems utilize surface TMS in six cognitive areas of the brain,
the left and right parietals, the left and right frontal lobes and Broca’s area
(integrates speech) and Wernicke’s area (integrates hearing) with an
innovation that combines the TMS with a relevant “cognitive event”.
For example, when TMS is applied to Broca’s area for 20 seconds, the
patient reads for 20 seconds, and repeat; TMS is applied to Wernicke’s
area for 20 seconds and a recording is played for 20 seconds.
In a small but compelling trial at Harvard-Beth Israel, the Alzheimer's
patients increased their cognitive ability by about 1/3, from 20 on the
standard ADAS-COGS scale, they realized an improvement by 5.83 points.
06/07/13 10:12
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 15
16. 06/07/13 10:12
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 16
Neuronix Treatment Procedure
How is it actually performed?
1. Pre-Treatment:
a) Perform an MRI scan on patient’s brain
b) Locate and mark brain regions of
interest
Broca
Wernicke
Dorsolateral
Prefrontal
cortex
Somatosensor
y Association
Cortex
3.Cognitive Training:
a) “Tailor made” exercises, set to fit with
patient’s specific abilities
2. Focused Magnetic Stimulation:
a) Position coil to stimulate specific region
Concurrent
TMS coil
Patient
Cognitive
Training
screen
• Treatment phase
– 30 sessions:
5 days a week, 6 weeks, 45-60 mins
– Each session: 3 regions per day
17. BRAINSWAY
Brainsway has patented deep TMS, penetrating 4-5 mm into the brain
compared to the 1.5-3mm penetration of standard TMS. Deep TMS is
the non-invasive analog to the very invasive deep brain electrode
implant.
Brainsway has CE approval for the following indications
Major Depressive Disorder (FDA indication)
Bipolar Depression
Post-Traumatic Stress Disorder
Schizophrenia (negative symptoms)
Parkinson's Disease
Chronic Pain
Brainsway has FDA approval for depression.
Brainsway has been doing clinical trials for indications such as PSTD,
bi-polar disorder, autism, Tourette’s, MS, MCI & Alzheimer’s and
ADHD.
06/07/13 10:12
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 17
18. Mazor Robotics
Mazor Robotics’ Renaissance™ , FDA approved, is transforming spine
surgery from freehand procedures to highly-accurate, state-of-the-art
robotic procedures, with less radiation—even for minimally invasive
surgery (MIS), scoliosis, and other complex spinal deformity cases.
Powered by Clinically Validated Technology -- Highly Accurate and Safe
Based on surgeons’ experience with thousands of SpineAssist® surgeries worldwide
tens of thousands of implants placed
No cases of permanent nerve damage
1.5 mm accuracy
Wide Range of Clinical Applications
Hardware and software tools enable a variety of spine procedures
Open, MIS, and percutaneous posterior thoracolumbar approaches
Scoliosis and other complex spinal deformities
Pedicle screws – short and long fusions
Transfacet screws and translaminar-facet screws
Osteotomies
Biopsies
06/07/13 10:12
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 18
19. CNS Companies in Clinical Trials
Brainsgate is developing a medical device to increase blood flow to the
brain to treat ischemic stroke and vascular.
Brainsway is using mesenchymal stem cells converted to secrete
neurotrophic factors to treat ALS, Lou Gehrig’s disease.
ElMindA’s Brain Network Activation Pattern technology is in trials to
give an objective measurement of concussion and other neuro-indications
by sophisticated processing of high-channel EEG information.
Neurim has successful phase 2 clinical trials using its Circadin to show
attenuation of cognitive deficits is early stage Alzheimer’s patients.
Nervomatrix is using automatic probes to diagnose and treat lower back
pain.
Novocure is doing a Phase 3 clinical trial for glioblastoma in the brain
using external, non-invasive AC generator to disrupt the tumor cells.
06/07/13 10:12
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 19
20. Summary
Neuro-cognitive and degenerative (CNS) diseases, with
Alzheimer’s leading, are among the most intractable and costly
and distressing diseases. Without effective therapies with
minimal side effects, these diseases will break the healthcare
systems, patients and caregivers.
Current therapies are inadequate and so many standard
pharmaceutical responses have failed in late stage trials.
Only the most innovative solutions will yield effective therapies.
Israel, with its history & culture of scientific innovative
innovation, government support & early recognition of the
challenges of CNS, is poised to be a leader in effective CNS
therapies.
How can we make Israel’s leadership known to the world?
06/07/13 10:12
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 20
21. For copy please email: howard.david.sterling@gmail.com
06/07/13
ISRAEL AS LEADER IN INNOVATIVE
NEUROLOGICAL THERAPIES 21